China invests heavily in biotechnology parks, vaccine R&D, and gene therapy startups. Its Belt & Road Health Initiative funds medical infrastructure and biotech research collaborations across Asia and Africa.
Chinese firms like Sinopharm and CanSino expand vaccine exports while negotiating technology transfer deals with developing nations. Intellectual property protections are improving under new Chinese patent laws, encouraging foreign biotech firms to co-develop drugs in China.
Global partnerships in genomics, cell therapies, and clinical trials position China as both a biotech supplier and a health diplomacy actor.
